Pharvaris to Host Virtual Expert Perspectives on HAE: Unmet Needs and Therapeutic Options Webinar on July 13
Pharvaris (Nasdaq: PHVS), a clinical-stage company, announced a virtual webinar on July 13, 2022, titled Expert Perspectives on HAE: Unmet Needs and Therapeutic Options.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Pharvaris (Nasdaq: PHVS), a clinical-stage company, announced a virtual webinar on July 13, 2022, titled Expert Perspectives on HAE: Unmet Needs and Therapeutic Options. The event will address the current landscape of Hereditary Angioedema (HAE), featuring insights from community members and physicians. Key speakers include Anthony J. Castaldo from HAE International, Dr. Marc A. Riedl from UCSD, Berndt Modig, and Dr. Peng Lu from Pharvaris. Registration for the live webcast is available on their website, with an archived replay accessible for 30 days post-event.
Details
News Market Reaction – PHVS
The recorded move for PHVS in the trading session of this news was +1.71%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
ZUG, Switzerland, July 06, 2022 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent HAE attacks, building on its deep-seated roots in hereditary angioedema (HAE), today announced that it will host a virtual webinar, titled Expert Perspectives on HAE: Unmet Needs and Therapeutic Options on Wednesday, July 13, 2022, at 10:00 a.m. ET/16:00 CET.
The virtual event will highlight several topics related to today’s HAE landscape, including a community member and physician perspective, as well as current therapeutic needs, followed by a Q&A session. Presenters for the event are:
- Anthony J. Castaldo, co-founder and President, HAE International (HAEi), and President, U.S. Hereditary Angioedema Association (HAEA)
- Marc A. Riedl, M.D., M.S., Professor of Medicine, Clinical Director of the US Hereditary Angioedema Association (HAEA) Angioedema Center at the University of California San Diego (UCSD), and the Training Program Director for Allergy/Immunology at UCSD
- Berndt Modig, Chief Executive Officer, Pharvaris
- Peng Lu, M.D., Ph.D., Chief Medical Officer, Pharvaris
To register for the live webcast, please visit https://ir.pharvaris.com/news-events/events-presentations in the News and Events section of the company’s website. Following the live webcast, an archived replay will be available for at least 30 days after the event.
About Pharvaris
Pharvaris is a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent HAE attacks, building on its deep-seated roots in HAE. By directly targeting this clinically proven therapeutic target with novel small molecules, the Pharvaris team aspires to offer people with all sub-types of HAE more effective and convenient alternatives to treat attacks, both on-demand and prophylactically. The company brings together the best talent in the industry with deep expertise in rare diseases and HAE. For more information, visit https://pharvaris.com/
Contact
Maryann Cimino
Director of Corporate Relations
maryann.cimino@pharvaris.com
+1-617-710-7305
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.